Mezzion Pharma Co.Ltd Cash Flow-to-Debt Ratio
Mezzion Pharma Co.Ltd cash flow-to-debt ratio. Mezzion Pharma Co.Ltd (140410) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2026, meaning its operating cash flow of ₩-4.75 Billion could theoretically repay 0% of its total liabilities (₩86.20 Billion) in one year. Check cash flow reinvestment rate of Mezzion Pharma Co.Ltd to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mezzion Pharma Co.Ltd (2012–2025)
Cash flow-to-debt ratio of Mezzion Pharma Co.Ltd from 2012 to 2025. Historical debt coverage capacity for Mezzion Pharma Co.Ltd across 12 annual periods. Check Mezzion Pharma Co.Ltd (140410) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Mezzion Pharma Co.Ltd Cash Flow-to-Debt Ratio by Year (2012–2025)
Mezzion Pharma Co.Ltd cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for Mezzion Pharma Co.Ltd. For the full cash flow conversion analysis, see Mezzion Pharma Co.Ltd (140410) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.59 Billion | ₩80.83 Billion | ▲ +69.0% |
| 2024 | -0.66x | ₩-18.49 Billion | ₩27.94 Billion | ▼ -84.4% |
| 2023 | -0.36x | ₩-11.02 Billion | ₩30.70 Billion | ▲ +17.4% |
| 2022 | -0.43x | ₩-12.07 Billion | ₩27.78 Billion | ▲ +39.0% |
| 2021 | -0.71x | ₩-15.07 Billion | ₩21.14 Billion | ▼ -81.8% |
| 2020 | -0.39x | ₩-7.38 Billion | ₩18.82 Billion | ▲ +69.9% |
| 2019 | -1.30x | ₩-20.88 Billion | ₩16.04 Billion | ▼ -6.3% |
| 2018 | -1.22x | ₩-21.72 Billion | ₩17.74 Billion | ▼ -93.4% |
| 2017 | -0.63x | ₩-13.21 Billion | ₩20.87 Billion | ▼ -349.0% |
| 2016 | -0.14x | ₩-6.08 Billion | ₩43.09 Billion | ▼ -422.4% |
| 2015 | 0.04x | ₩1.77 Billion | ₩40.52 Billion | ▼ -94.5% |
| 2012 | 0.79x | ₩3.14 Billion | ₩3.97 Billion | — |